In a conference call announcing the results of its first quarter as a fully merged company, Bruker Biosciences reported tough times in x-ray crystallography amid booming mass spec sales.
In a conference call announcing the results of its first quarter as a fully merged company, Bruker Biosciences reported tough times in x-ray crystallography amid booming mass spec sales.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.